Loading stock data…
VANI
$1.36+0.02 (+1.49%)
Market ClosedLast close May 1
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vivani Medical, Inc. in the Healthcare sector is trading at $1.36. The stock is currently 29% below its 52-week high of $1.92, remaining 1.5% above its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why VANI maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.36
Potential Upside
5%
Whystock Fair Value$1.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commer...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$112.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.00%
Volume
Today's trading volume
69,880
Recent News
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vivani Medical (VANI) to $3.50 from $4 and keeps a Buy rating on the shares after the company recently reported its 2025 results, citing an increased share count for the firm’s lowered target. The firm believes NPM-139 is uniquely positioned to potentially offer efficacy comparable to Wegovy while requiring only once or twice yearly administration, the analyst tells investors.Easter Sale - 70% Off TipRanksUnlock hedge fund-level
Vivani Medical: Q4 Earnings Snapshot
ALAMEDA, Calif. AP) — Vivani Medical, Inc. VANI) on Thursday reported a loss of $6.6 million in its fourth quarter.
Insiders Are Still Scooping Up Under Armour and WR Berkley Shares
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
GameStop CEO Picks Up 1M Shares, and Other Insiders Return to the Buy Window
The CEO of GameStop just picked up a million shares, and insiders are returning for more shares of Under Armour, Mission Produce, and more.